The abstract is read at the publisher; the summary is JClub's.
CD39/CD73 adenosinergic pathway activity is increased in human NSCLC tumor microenvironments, with preferential expression in lung adenocarcinomas linked to elevated PD-L1 and effector T cell infiltration.
- Why it matters: CD73-blocking plus PD-L1 antagonism benefits only a subset of resectable NSCLC patients, so understanding pathway context and how other therapies reshape it is needed for better selection and design.
- What they did: The study used multiplexed quantitative immunofluorescence and spatial transcriptomics across multiple NSCLC patient cohorts, complemented by in vitro cultured NSCLC cell experiments.
- The result: The pathway shows asymmetric tumor microenvironment distribution with limited intratumor spatial heterogeneity, and cancer cell CD73 is differentially modulated by proinflammatory cytokines and systemic radio-chemotherapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.